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Abstract: The primary objective of this study was to assess whether a hospital-based antimicrobial stewardship team (H-AST) from an unaffiliated hospital
could decrease inappropriate fluoroquinolone use at a local, long-term care facility (LTCF). The H-AST created a multi-faceted intervention campaign that included antibiogram development, provider and family education, and a telephone hotline. Pre- and post-intervention mean defined daily doses per 1000 resident days
for antimicrobials were calculated to determine the impact of the campaign. The
campaign resulted in a 38.70% decrease in ciprofloxacin utilization, a 16.20% decrease in total FQ consumption, and an 11.68% in total antibiotic consumption.
In addition, during the study period the rate of Clostridium difficile infection decreased by 19.47%. Collaboration with a H-AST had a positive impact on antibiotic prescribing at this LTCF.
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T

he steadily increasing rate of antimicrobial resistance is a major concern
in the health care community. In order to combat this threat, hospitals
across the nation have successfully implemented antibiotic stewardship
teams (ASTs). These programs have improved treatment outcomes, limited
antimicrobial resistance, and decreased the rates of adverse drug events.1 The
principles of successful ASTs have contributed to the creation of the White
House’s National Action Plan for Combating Antibiotic-Resistant Bacteria,
which focuses on improving stewardship in health care settings, including
long-term care facilities (LTCFs). In combination with the Centers for Disease
Control (CDC), Centers for Medicare/Medicaid Services (CMS), and Agency for Healthcare Research and Quality (AHRQ), the National Action Plan,
which will be executed over 5 years, includes implementing antibiotic stewardship programs in LTCFs to decrease the overuse and misuse of antimicrobial
agents, which result in antibiotic resistance and adverse effects including Clostridium difficile colitis.2
Antimicrobial agents account for 40% of prescribed medications in LTCFs.
Additionally, 25–75% of systemic antimicrobial use in LTCFs is reportedly
inappropriate.3 In the geriatric population, the most common infections include urinary tract infection (UTI), skin and soft tissue infection (SSTI), and
respiratory tract infection (RTI). Asymptomatic bacterial colonization may
result in inappropriate diagnosis of one of these infections, leading to treatment with broad-spectrum antimicrobials such as fluoroquinolones. This class
of antimicrobials has been associated with an increased risk of Clostridium
difficile infection (CDI) and multidrug resistant organisms (MDRO).4, 5 One
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commonly employed initiative to decrease CDI rates in
hospitals is to restrict the use of the fluoroquinolone class
of antimicrobials.
With the current lack of antimicrobial stewardship programs in LTCFs, hospital-based antimicrobial stewardship
teams (H-ASTs) have the opportunity to improve antimicrobial use through collaboration with a local LTCF. Residents
in LTCFs act as reservoirs for MDRO and CDI, and approximately 20% of hospital admissions are preceded by a LTCF
transfer or result in a LTCF admission upon discharge.6 The
transfer of LTCF patients to emergency departments and
hospitals contributes to the spread of resistance in both institutions.7 Hospital initiatives to decrease the incidence of
CDI should take into account this patient sharing. Extending hospital initiatives to a LTCF that commonly transfers
patients to that hospital may have a positive effect at both
institutions. This study assessed the effect of a H-AST on
the use of fluoroquinolones, overall antibiotic consumption,
and CDI rates at a neighboring, unaffiliated LTCF.
The primary objective of this study was to decrease inappropriate fluoroquinolone use in a LTCF through education
and open lines of communication between the H-AST and
LTCF. Secondary outcomes included decreasing overall antibiotic use in the LTCF by decreasing the treatment rates
of UTI, RTI, and SSTI, and reducing the rate of CDI. To
achieve these goals, the H-AST created a multi-faceted intervention campaign which included four major initiatives:
1) creation of a LTCF urinary antibiogram; 2) an educational in-service for providers on appropriate treatment of UTI,
SSTI and RTI; 3) an educational event specific for family
members discussing the risks of overusing antimicrobial
agents; and 4) a telephone hotline for the LTCF to contact
the H-AST for questions. Pre- and post-intervention mean
dail defined dose (DDD) per 1000 resident days (RD) data
for antimicrobials were calculated to determine the impact
of the campaign.

Methods
A memorandum of understanding was created between a
431-bed community teaching hospital and a 520-bed, long-

term, skilled nursing facility. The LTCF medical director,
nursing manager, and infection prevention nurse collaborated with the H-AST, consisting of infectious disease physicians, an infectious disease pharmacist, a clinical pharmacist,
the director of pharmacy, the microbiology manager, and
the infection prevention manager.
The reference microbiology laboratory provided data on
urinary pathogen sensitivities from January 2013 to September 2013 based on Clinical and Laboratory Standards Institute (CLSI) standards.8 The three most commonly isolated
urinary pathogens were Escherichia coli, Klebsiella pneumonia, and Proteus mirabilis. The antibiogram was distributed
to the providers via email highlighting the Escherichia coli
ciprofloxacin sensitivity of 56% (Figure 1). This data was
also incorporated into the educational campaign.
The education campaign focused on creating treatment
guidelines for the three most common disease states that affect LTCF residents: UTI, SSTI, and RTI. Supporting literature was collected and antibiotic treatment recommendations
were made based on evidence-based medicine, antibiogram
results, antimicrobial risk of developing CDI, and incidence of adverse effects in the LTCF population. A pocket
card outlining the recommendations was developed for each
disease state (Figure 2). In addition, a 60-minute presentation summarizing treatment recommendations was prepared.
Highlights of the presentation included the rationale for not
treating asymptomatic UTI, avoiding the use of fluoroquinolones empirically for UTIs based on antibiogram data, differentiating between viral and bacterial respiratory infections,
discouraging the use of fluoroquinolones for empiric treatment of SSTI, and recommending length of antimicrobial
therapy for these infections. In addition, common causes of
altered mental status in the elderly and risk factors for the
development of CDI were reviewed. The presentation, which
was given by an infectious disease physician, was attended
by LTCF physicians, nurse practitioners, physician assistants,
consultant pharmacists, and administrators. At the conclusion of the educational program, the providers were given a
telephone number for both the infectious diseases physician
on call and the antibiotic stewardship pharmacist. They were

Organism

Cipro

Levo

Gentamicin Tobramycin Doxycycline

E Coli
n = 80

56

56

84

92

Proteus
n = 29

55

55

90

95

Bactrim

Nitrofurantoin

83

69

89

0

76

0

Figure 1. Urinary Tract Pathogen Antibiogram for Long-Term Care Facility
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Criteria for Treatment of a Symptomatic UTI

Bacteriuria

Symptoms of a UTI plus Pyuria plus
A Positive Urine Culture
Symptoms of a UTI:
-Fever and/or Chills
-Otherwise unexplained abrupt change in mental status
-New or increased
• Incontinence
• Flank pain
• Burning or pain during urination
• Frequency
• Urgency

Definition:
Significant bacteria in the urine
without any signs or symptoms of
a urinary tract infection

Keep in Mind: Most elderly patients have chronic urinary symptoms such as incontinence, nocturia,
frequency and/or urgency. In order to be a symptom of a UTI these must change from baseline!

Empiric Antibiotic Choice:
Nitrofurantoin (if on Warfarin) or
Bactrim (if not on Warfarin)

Women with no catheter:
7 days or
10-14 days
if severe infection

Streamlined Antibiotic Choices:
E. Coli
1st line

Proteus

Bactrim

2nd line

Nitrofurantoin

3rd line

Doxycycline

Dosing
Regimens

Men with no catheter:
10-14 days

Bactrim

Renal Function (CrCl)
≥60 ml/min

Bactrim

30-59 ml/min

1 DS tab BID

Nitrofurantoin 100 mg BID
Doxycycline

MIC

15-29 ml/min

<15 ml/min

E Coli

Proteus

1 DS tab qday

Do not use

69

76

89

0

83

0

Do not use if CrCl <40 ml/min

100mg BID

Do not use

Figure 2. Prescriber Pocket Guide for Urinary Tract Infection
Abbreviations: UTI, urinary tract infections; DS, double strength; BID, twice a day.
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Table 1. Comparison of 12-month Average DDD/1000 RD FQ Usage Pre- and Post-intervention
Fluoroquinolone

Pre-intervention
DDD/1000 RD

Post-intervention
DDD/1000 RD

% Change

P-value (95% CI)

Ciprofloxacin

7.08 ± 2.49

4.34 ± 1.98

- 38.70%

0.02 (0.58 – 4.91)

Levofloxacin

6.16 ± 2.46

6.72 ± 2.41

+ 9.09%

0.65 (-3.21 – 2.09)

Moxifloxacin

0.34 ± 0.31

0.32 ± 0.38

- 5.88%

0.93 (-0.32 – 0.34)

Abbreviations: mean DDD/1000 RD, defined daily doses per 1000 resident days; FQ, fluoroquinolone.

informed that this number could be called 24 hours a day 7
days a week for any infectious disease related questions.
When the LTCF representatives met with the H-AST,
it was identified that antibiotics are often prescribed in a
LTCF due to pressure on prescribers by family members.
This is also well established in other relevant literature.3 To
address this concern, a 60-minute educational presentation
titled “To Treat or Not to Treat” was developed for family members and presented at one of the monthly family
council meetings. This was followed by a question and answer session by the infectious disease physician. Similar to
the provider presentation, topics included UTI, SSTI, RTI,
and CDI. This presentation included basic true-and-false
questions to help engage the audience and gauge their baseline knowledge. For example, the audience was asked: “If
my family member has bacteria in their urine, should he/
she receive an antibiotic?” In addition, family pamphlets
were prepared for each of the disease states. Each pamphlet
clearly explained when the use of antibiotics was deemed
necessary and the adverse effects associated with inappropriate antibiotic use (Figure 2). Written material was reviewed by the patient education department at the hospital
to ensure a reading level of sixth grade or lower. Pamphlets
were distributed on each care unit in the LTCF.

Data Collection
Pre- and post-intervention data was collected monthly
from July 2012 to June 2013 and July 2013 to June 2014,
respectively. Monthly inventory usage reports were generated by the dispensing pharmacy for all antibiotics prescribed at the LTCF, including doses sent to fill automated
dispensing cabinets. For each antibiotic, the total grams
dispensed were converted to a DDD, as defined by the
World Health Organization.9 All DDDs were standardized
per 1000 RD. Pre- and post-intervention mean DDD per
1000 RD data for ciprofloxacin, levofloxacin, and moxifloxacin were calculated. Pre- and post-mean data for total
antibiotic consumption was calculated and divided by antibiotic class. The infection prevention nurse at the LTCF
provided monthly totals of RD, as well as rates of UTI,
16
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SSTI, RTI, and CDI cases per 1000 RD as defined by
standard CDC definitions.10

Analysis
Comparison of the 12-month mean DDD per 1000 RD
pre- and post-intervention for ciprofloxacin, levofloxacin,
moxifloxacin, fluoroquinolones, penicillins, cephalosporins, macrolides, tetracyclines, nitrofurantoin, sulfonamides, and total antibiotic utilization were analyzed using
a paired t test. The rates of UTI, SSTI, RTI, and CDI from
the pre- and post-intervention periods were also analyzed
using a paired t test. Results were determined to be significant with a 2-tailed P < 0.05. Analysis was performed using
IBM® SPSS® Statistics Version 22. A post-hoc analysis was
performed in June 2015, 12 months after the intervention
period was over, to determine if the interventions had lasting effects on prescribing habits of ciprofloxacin and FQ
DDD per 1000 RD at the LTCF.

Results
A significant 38.70% decrease was seen in ciprofloxacin
utilization in the post-intervention period from 7.08 to
4.34 DDD per 1000 RD P = 0.02 (Table 1). Levofloxacin and moxifloxacin use did not show a statistically significant change, going from 6.16 to 6.72 and 0.34 to 0.32
DDD per 1000 RD respectively (P = 0.65 and 0.93). Total
FQ consumption (ciprofloxacin, levofloxacin, and moxifloxacin) also did not change significantly, decreasing from
13.58 to 11.38 DDD per 1000 RD P = 0.31 during the
intervention period.
Total antibiotic consumption decreased 11.68% from
82.33 to 72.71 DDD per 1000 RD (P = 0.06) during the
intervention period. In addition to a 16.20% decrease usage
in the FQ class, there was also a decrease of 24.49%, 25.34%,
25.63%, and 14.29% in the cephalosporins, nitrofurantoin,
macrolides, and tetracycline classes respectively (Table 2).
Sulfonamide use increased 39.45% from 2.18 DDD per
1000 RD to 3.04 in the post-intervention period. Post-intervention penicillin usage increased 10.23% comparatively P
= 0.20. When reviewed at an individual antibiotic level, the
www.annalsoflongtermcare.com
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Table 2. Comparison of 12-month Average DDD/1000 RD for Separate Antibiotic Classes and Total
Antibiotic Usage Pre- and Post-intervention
Antibiotic Class

Pre-intervention
DDD/1000 RD

Post-intervention
DDD/1000 RD

% Change

P-value (95% CI)

Penicillins

19.26 ± 5.79

21.23 ± 4.92

+ 10.23%

0.20 (-5.15 – 1.21)

Cephalosporins

12.78 ± 4.56

9.65 ± 2.26

- 24.49%

0.06 (-0.15 - 6.41)

Macrolides

6.36 ± 2.60

4.73 ± 2.86

-25.63%

0.24 (-1.25 – 4.50)

Tetracyclines

22.33 ± 9.70

19.14 ± 4.88

- 14.29%

0.29 (-3.10 – 9.48)

Fluoroquinolones

13.58 ± 3.50

11.38 ± 4.07

- 16.20%

0.31 (-2.38 – 6.78)

Sulfonamides

2.18 ± 1.06

3.04 ± 1.40

+ 9.45%

0.13 (-2.02 – 0.30)

Nitrofurantoin

1.97 ± 1.17

.47 ± 0.64

-25.34%

0.22 (-0.34 – 1.33)

Total Antibiotic Use

82.33 ± 12.23

72.71 ± 6.80

- 11.68%

0.06 (-0.44 – 19.67)

Abbreviations: mean DDD/1000 RD, defined daily doses per 1000 resident days.

LTCF utilized more amoxicillin (23.70 vs 31.12 DDD per
1000 RD) and ampicillin (18.9 vs 40.1 DDD per 1000 RD)
with a decrease in cefuroxime (59.8 vs 50 DDD per 1000
RD) and ceftriaxone (22.5 vs 9.42 DDD per 1000 RD) in
the post-intervention period.
Overall FQ consumption in June of 2015 was 10.03
DDD per 1000 RD in comparison to 11.38 DDD per 1000
RD during the intervention period (July 2013-June 2014)
and 13.58 in the pre-intervention period.
A comparison of infection rates per 1000 RD pre- and
post-intervention showed a 5.51% decrease in UTI diagnosis/treatment from 1.71 to 1.61 (P = 0.28) and a 5.73% decrease in RTI from 1.35 to 1.27 (P = 0.67) (Table 3). There
was an 11.10% increase in the rate of SSTI during the postintervention period from 0.92 to 1.04 (P = 0.27). The rate of
CDI in the LTCF decreased by 19.47% from 0.094 to 0.076
(P = 0.58) in the post-intervention period.

Discussion
Our results confirm that the collaboration of a H-AST
with a LTCF can result in a significant 38.7% decrease in
ciprofloxacin usage with a decrease trend in overall antibiotic usage. Antibiotic stewardship interventions that are
commonly employed in an acute-care setting such as the
creation of antibiograms, treatment guidelines, and educational materials are not readily available in LTCF. The use
of a H-AST team to fill this gap in the LTCF setting and
provide microbiology data, provider education, and a 24hour hotline, as done in this study, is a novel concept.
The four initiatives employed by the H-AST had the biggest impact on ciprofloxacin prescribing. The LTCF antibiogram results showed that only 56% of facility E coli were
susceptible to ciprofloxacin, providing clear evidence that
www.annalsoflongtermcare.com
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ciprofloxacin is an inappropriate agent for empiric therapy
of a symptomatic UTI in this population. In addition, both
the provider and family educational campaign focused on
decreasing inappropriate prescribing for asymptomatic bacteriuria in the LTCF population. With these initiatives, the
H-AST was able to decrease the treatment rate of UTI by
5.51% in the post-intervention period, which may have
also contributed to the decrease in ciprofloxacin use. The
H-AST was not able to significantly decrease levofloxacin or
moxifloxacin prescribing.
In addition, the interventions to decrease ciprofloxacin
prescriptions resulted in a decrease in overall antibiotic
consumption and a shift in antibiotic classes prescribed at
the LTCF. Overall antibiotic consumption in the LTCF decreased by 11.68%. Although this decrease did not quite
reach statistical significance (P = 0.06), the trend is promising. One of the main goals of the H-AST was to educate
prescribers and patient families on the risks of treating asymptomatic bacteriuria and viral infections. Studies on the
inappropriate treatment of these disease states in the elderly
population have shown an increase risk of MDRO and antimicrobial adverse effects, without a change in morbidity
and mortality.11,12 The number of reported cases of UTI and
RTI decreased during the intervention period but did not
reach statistical significance. Treatment guidelines and educational sessions reinforced shorter treatment courses for
UTI, RTI, and SSTI, which may have also contributed to
the decrease in overall antibiotic use at the LTCF.
The H-AST also had an impact on promoting antimicrobial classes with a lower incidence of causing CDI. Over
the 12-month period, there was a decrease in cephalosporin,
tetracycline, and macrolide prescribing with an increase in
the use of agents in the penicillin and sulfonamide classes.
June 2016 • Annals of Long-Term Care®
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Table 3. Comparison of Infection Rates per 1000 RD Pre- and Post-intervention
Infection

Pre-Intervention

Post-Intervention

% Change

value (95% CI)

UTI

1.71 ± 0.21

1.61± 0.24

- 5.51%

0.28 (-0.088-0.28)

RTI

1.35 ± 0.47

1.27 ± 0.44

- 5.73%

0.67 (-0.31 – 0.46)

SSTI

0.92 ± 0.19

1.04 ± 0.33

+11.10%

0.27 (-0.33 – 0.10)

CDI

0.094 ± 0.09

0.076 ± 0.59

-19.47%

0.58 (-0.053 – 0.090)

Abbreviations: RD, resident days; UTI, urinary tract infection; RTI, respiratory tract infection; SSTI, skin and soft tissue infection;
CDI, Clostridium difficile infection.

During the post-intervention period, broad-spectrum cephalosporins, such as ceftriaxone and cefuroxime, decreased by
13.08 and 9.8 DDD per 1000 RD, while penicillins, such as
amoxicillin and ampicillin, increased by 7.42 and 21.2 DDD
per 1000 RD. The increase in aminopenicillins in the postintervention period may have been the result of promoting
these agents for the treatment of nonpurulent cellulitis during
the educational campaign as recommended in current SSTI
guidelines from the Infectious Disease Society of America.13
This therapy may have replaced the use of cephalosporins or
the inappropriate use of fluoroquinolones for SSTI. The use
of sulfamethoxazole-trimethoprim also increased in the postintervention group by 39.45%. The provider education sessions highlighted the use of sulfamethoxazole-trimethoprim
as a first-line option for the empiric treatment of UTIs (Figure 2) as well as Staphylococcal skin infections. Despite the
significant decrease in ciprofloxacin use, decrease in overall
antibiotic consumption, and shift away from high-risk CDI
inducing antibiotics, there was not a statistically significant
decrease in the rate of CDI. This is likely due to the fact that
CDI rates at the institution were already reasonably low.
LTCF providers and nursing staff commonly state that
a large obstacle to appropriate antimicrobial prescribing is
family pressure. Providing family member education was a
unique element to this stewardship initiative. Providing an
education session with a question-and-answer period and
providing easy-to-read pamphlets (Figure 3) throughout the
facility, explaining the harm of inappropriate prescribing,
may have contributed to a decrease in family member pressure on medical and nursing staff, overall antibiotic use, and
treatment rates for UTI and RTI.
Other LTCF initiatives that have been reported to decrease inappropriate antimicrobial prescribing have included
education, prescriber feedback, nursing audit, guideline development, and infectious disease physician consultation.14-18
One initiative studied the effect of printed educational material in conjunction with periodic physician scorecards on
adherence to the treatment guidelines for UTI, RTI, SSTI,
18
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and septicemia of unknown origin over a 9-month period.16
Education and prescribing feedback significantly decreased
non-adherent prescribing by 64% (odds ratio 0.35 95%; CI
0.18-0.73) at the 6-month follow-up, but this significance
was not maintained at the 9-month interval. Another initiative provided a UTI treatment algorithm to LTCF physicians
and nurses along with written material consisting of pocket
cards, posters, real-time reminders, and outreach visits.17 For
that initiative, there was a statistically significant decrease in
the proportion of total antibiotics prescribed for UTI in the
intervention group compared to the paired controls 28%
to 39% (weighted mean difference, -9.6%; range, -16.9 to
-2.4%), although there was no significant change in urinary
cultures obtained, hospitalization, or mortality between
groups. Similar to the previous study, the impact of education was not maintained at the 12-month post-intervention.
In our study, the H-AST collected data 12 months after the
intervention period (June 2105) to assess the durability of
the effect on FQ consumption. One year following the intervention, FQ use had declined further, from 11.38 DDD per
1000 RD at the end of the intervention to 10.03.
Previous studies have shown that decreasing the use of
fluroquinolone antibiotics results in lower CDI rates.19,20 A
community hospital decreased their rate of CDI from 1.6 to
1.2 cases per 1000 RD by restricting FQ usage from 17.6 to
6.0 DDD per 1000 RD in addition to implementing environmental cleaning procedures. The baseline rate of CDI at
the LTCF where our study was conducted was low, preventing us from showing a statistically significant decline in CDI
rates, however, the measured rate did decline from 0.094 to
0.076 post-intervention. In addition, it is unknown what the
effect of decreasing CDI rates in a LTCF has on the transferring hospital.
Controlling the use of fluoroquinolones in a LTCF may
also have an impact on the incidence of the NAP-1/027/B1
strain of CDI.21 Fluoroquinolones are known to single out
the NAP-1/027/B1 strain that can be associated with greater
toxin production and more severe disease, especially in the
www.annalsoflongtermcare.com
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How can you
help?
It is a natural and common
feeling to want to ask that your
family member be treated with
antibiotics every time a urine
culture comes back positive, or
they have a symptom that is
consistent with a urinary
tract infection.
Our hope is that by
educating you on the appropriate
and inappropriate times to treat
a urinary tract infection, you can
help us to decrease the
use of antibiotics when they
are not necessary

What do we need
from you?
TRUST!

The doctors, physcian assistants and
nurses all know when they should use
antibiotics. They won’t let your loved
one go untreated if they should be.

Why is it important to
not use antibiotics when
they aren’t necessary?
There are several negative results
of using antibiotics more than
necessary:
1. Adverse Drug Reactions
2. Resistance
a.Every time an organism is
exposed to an antibiotic, it gets
smarter. Eventually, they get so
smart that our medications no
longer kill them
b.This is especially an issue in
Long Term Care facilities across
the country so we need to do
our best to prevent it from
happening at Loretto
3. Clostridium Difficile Infection
a.This infection is caused by
exposure to antibiotics
b.The most common symptom
is uncontrollable diarrhea
c.Antibiotic use is the most
common risk factor for getting
this infection

Urinary Tract
Infections
To Treat or Not to Treat?

St. Joseph’s Antibiotic
Stewardship Team

Figure 3. Pamphlet for Family Members

elderly population.22 A prevalence study showed that hospital
patients admitted from a LTCF were four times more likely
to be infected with this strain than patients admitted from
home.22 It is unknown if the decrease in FQ usage had an effect on the occurrence of the NAP-1 strain at the LTCF, since
this data was unavailable from the microbiology laboratory.
Despite the ability to collect monthly antibiotic usage
data, the lack of electronic medical records at the LTCF made
it difficult to track the exact indication for FQ use. The antibiotic usage data were captured by pharmacy dispensing
data. This may not have accurately captured doses received
since the dispensing pharmacy did not credit doses that were
not administered. In addition, the use of DDD in the elderly population may over-predict usage as these patients are
commonly on lower, total daily doses based on reduced renal function. Infection data were evaluated using definitions
of UTI, SSTI, and RTI as reported by the infection control
nurse at the institution and may have included patients with
www.annalsoflongtermcare.com
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non-infectious or viral causes. These definitions, however,
were consistent throughout the study period. An additional
limitation was that the number of phone calls made from
the LTCF to the on-call physician and pharmacist were not
documented during the study period. Finally, the LTCF performed environmental changes during the pre-intervention
period that could have affected the CDI rates during the
post-intervention period.
This study was not able to identify the potential impact of
antibiotic stewardship in a LTCF on the hospital, although it
is anticipated to be beneficial. Future research needs to focus
on the impact of transitions in care on CDI and MDRO
in LTCF patients. During collaborative meetings with the
LTCF providers, it was identified that patients transferred
to the hospital’s emergency department with confusion or
delirium were inappropriately prescribed antimicrobials, including ciprofloxacin, and then sent back to the LTCF to
complete the therapy. To help combat this issue, the H-AST
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provided an interactive, case-based in-service to the emergency department (ED) providers on patients transferred
from the LTCF to the ED with asymptomatic UTIs after
the intervention period was completed. This reiterates the
importance of recognizing the impact of transition of care on
inappropriate antimicrobial prescribing. Future research also
needs to focus on education programs for LTCF nursing staff
and consultant pharmacists on the appropriate prescribing of
antimicrobials in this population.

Conclusion
A minimal resource education campaign at a LTCF performed
by a H-AST was able to have a large impact on decreasing ciprofloxacin prescribing for UTI and asymptomatic bacteriuria
with a statistically significant decrease in ciprofloxacin consumption by 37.7% over a 12-month period. This may have
contributed to a decreased incidence of CDI by 19.47%. In
2011, the AHRQ Healthcare Cost and Utilization Project estimated that 21.5% of hospital discharges of older adults were
either preceded by a LTCF transfer or resulted in admission
to a LTCF.6 This high patient flow amongst institutions represents a large risk for the transmission of MDRO including
CDI. With this influx, H-ASTs would be advised to focus on
more than just antimicrobial use within the hospital walls. u
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